Dilanubicel clinical trials
Also written NLA101.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses dilanubicel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2018 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Fred Hutchinson Cancer Center (2) · Nohla Therapeutics, Inc. (2)
Studies
Open first, then newest update. How each study uses dilanubicel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesActive, not recruitingPhase 2Fred Hutchinson Cancer CenterNCT03399773Written as Dilanubicel
- Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic CancersTerminatedPhase 2Fred Hutchinson Cancer CenterNCT04083170Written as Dilanubicel
- NLA101 in Adults Receiving High Dose Chemotherapy for AMLTerminatedPhase 2Nohla Therapeutics, Inc.NCT03301597Written as NLA101
- Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedPhase 1Nohla Therapeutics, Inc.NCT01701323Written as Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Given beside what is tested · 1 — dilanubicel is usual care or a partner of the new treatment
Codes
What other systems call dilanubicel · ClinicalTrials.gg INT016589
- UNII (FDA) FR89SC8CT4DILANUBICELOne source FDA
- NCI Thesaurus C146992DilanubicelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FR89SC8CT4 | DILANUBICEL | One source FDA |
| NCI Thesaurus | C146992 | Dilanubicel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.